PEX3 Antibody - #DF4282

Fig. 4. AST promotes cytoskeletal remodeling and peroxisome function under high-glucose conditions. (a) Schematic of the experimental workflow for transcriptomic analysis of HUVECs treated with AST under high-glucose (HG) conditions, including RNA-seq, GSEA, and downstream validation. (b) Volcano plot showing differentially expressed genes (DEGs) between HG and AST-treated groups. Red and blue dots represent upregulated and downregulated genes, respectively. (c) Heatmap of hierarchical clustering illustrating distinct gene expression patterns between HG and AST-treated groups. (d) GSEA of the peroxisome pathway in AST-treated cells, showing significant enrichment. Relative mRNA levels of PEX3 and PEX19 were analyzed by RT-qPCR. (e) Representative immunohistochemistry (IHC) staining for PEX3 and PEX19 in wound tissue from Control, Diabetes, and AST@GelMN groups, with quantification of staining intensity. (f) Western blot analysis of PEX3 and PEX19 expression under HG conditions with or without AST treatment. (g) Phalloidin staining for F-actin showing cytoskeletal remodeling in Control, HG, and AST-treated cells. Quantification of F-actin intensity is provided. (h) GO analysis of DEGs. (i) Representative IHC staining for Actin in wound tissues from Control, Diabetes, and AST@GelMN groups, with quantification of staining intensity. (j) Western blot analysis of RhoA, Cdc42, and Actin under HG conditions with or without AST treatment. Quantification of protein levels is shown. (k) KEGG pathway analysis of DEGs. (l) Schematic representation illustrating mechanism of AST. The data are represented as mean ± SD (n = 5). ∗∗P < 0.01, ∗∗∗P < 0.001, ∗∗∗∗P < 0.0001. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)